(LLY) Eli Lilly - Ratings and Ratios
Diabetes Treatments, Cancer Medications, Immunology Drugs
LLY EPS (Earnings per Share)
LLY Revenue
Description: LLY Eli Lilly
Eli Lilly and Company is a leading pharmaceutical company that develops and markets a diverse portfolio of human pharmaceuticals globally. The companys product portfolio includes a range of diabetes treatments, such as Basaglar, Humalog, and Trulicity, as well as oncology products like Alimta, Cyramza, and Verzenio. Additionally, Eli Lilly offers treatments for various other conditions, including rheumatoid arthritis, psoriasis, and obesity.
From a business perspective, Eli Lilly has established collaborations with several companies, including Incyte Corporation, Boehringer Ingelheim Pharmaceuticals, and F. Hoffmann-La Roche Ltd, to advance its research and development capabilities. The companys strong research pipeline and strategic partnerships are key drivers of its growth. Key Performance Indicators (KPIs) such as Revenue Growth Rate, Research and Development (R&D) expenditure as a percentage of revenue, and Product Approval Rate are crucial in evaluating the companys performance.
In terms of financial performance, Eli Lillys Market Capitalization stands at approximately $711.9 billion, indicating its significant presence in the pharmaceutical industry. The companys Return on Equity (RoE) of 76.92% suggests a strong ability to generate profits from shareholder equity. Other relevant KPIs include the companys Debt-to-Equity Ratio, Operating Margin, and Earnings Per Share (EPS) growth rate, which can provide insights into its financial health and profitability.
To further analyze Eli Lillys stock performance, technical indicators such as the Relative Strength Index (RSI), Bollinger Bands, and Moving Averages can be used. For instance, the companys current price is near its support level of $798.1, and the SMA20 is above the SMA50, indicating a potential bullish trend. However, the SMA200 is above the current price, suggesting a potential resistance level.
Additional Sources for LLY Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
LLY Stock Overview
Market Cap in USD | 711,914m |
Sector | Healthcare |
Industry | Drug Manufacturers - General |
GiC Sub-Industry | Pharmaceuticals |
IPO / Inception | 1978-01-13 |
LLY Stock Ratings
Growth Rating | 63.7 |
Fundamental | 63.9 |
Dividend Rating | 69.1 |
Rel. Strength | -5.57 |
Analysts | 4.24 of 5 |
Fair Price Momentum | 859.69 USD |
Fair Price DCF | 5.87 USD |
LLY Dividends
Dividend Yield 12m | 0.90% |
Yield on Cost 5y | 4.51% |
Annual Growth 5y | 11.93% |
Payout Consistency | 99.5% |
Payout Ratio | 40.7% |
LLY Growth Ratios
Growth Correlation 3m | -7.7% |
Growth Correlation 12m | -53.3% |
Growth Correlation 5y | 97.1% |
CAGR 5y | 37.04% |
CAGR/Max DD 5y | 1.47 |
Sharpe Ratio 12m | 0.65 |
Alpha | -28.60 |
Beta | 0.909 |
Volatility | 32.99% |
Current Volume | 4104.8k |
Average Volume 20d | 3032.3k |
Stop Loss | 738.7 (-3%) |
As of July 18, 2025, the stock is trading at USD 761.50 with a total of 4,104,757 shares traded.
Over the past week, the price has changed by -3.69%, over one month by -3.76%, over three months by -9.16% and over the past year by -15.34%.
Yes, based on ValueRay´s Fundamental Analyses, Eli Lilly (NYSE:LLY) is currently (July 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 63.93 and therefor a positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of LLY is around 859.69 USD . This means that LLY is currently undervalued and has a potential upside of +12.89% (Margin of Safety).
Eli Lilly has received a consensus analysts rating of 4.24. Therefore, it is recommended to buy LLY.
- Strong Buy: 16
- Buy: 7
- Hold: 4
- Sell: 1
- Strong Sell: 1
According to our own proprietary Forecast Model, LLY Eli Lilly will be worth about 975.2 in July 2026. The stock is currently trading at 761.50. This means that the stock has a potential upside of +28.07%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | 952 | 25% |
Analysts Target Price | 952 | 25% |
ValueRay Target Price | 975.2 | 28.1% |